TLR8 agonist 2 (Example 1) increases the levels of TNF-α, IL-12p40, IFN-γ, and IFN-α with EC 50 values 105 nM, 26 nM, 29 nM, and 2800 nM, respectively, in human peripheral blood mononuclear cells (hPBMC)[1].

The pharmacokinetic related parameters of TLR8 agonist 2 (Example 1) in mice administered with the intravenous administration of 1 mg/kg and the oral administration of 5 mg/kg are detected. The T 1/2 of TLR8 agonist 2 are 0.25 h (1 mg/kg i.v.) and 0.5 h (5 mg/kg p.o.), the AUC last are 450 ng/mLhr (i.v.) and 624 ng/mLhr (p.o.). And for oral administration, the bioavailability (%F) is 27.7%[1]